This document provides an overview of financial information for some pharmaceutical companies. It discusses profit and loss statements for Apple and Pfizer, highlighting Lipitor's peak sales and cumulative revenue from 1996-2012. Details are given on the balance sheets and cash flow statements of Galapagos, a small biotech company, showing assets, equity, and liabilities. The document notes there have been many deals between large pharmaceutical firms and small biotechs involving mergers, alliances, and licensing agreements.

1. SOME PHARMA FINANCIALS
PROF. DR. WOUTER DE MAESENEIRE

2. DISCLAIMER
 I am not a pharma/healthcare expert
 But I did quite some work for student in-
company projects or customized trainings for
 Pfizer, J&J (Janssen), Arseus, Capsugel, UCB,
Boehringher-Inghelheim,…
 IRC MFM last year: UCB
 I wrote a case on BigPharma vs Small Biotech
FSA
 I’ll give a broad overview of some of the issues

3. © Vlerick Business School3

4. © Vlerick Business School
PROFIT AND LOSS ACCOUNT/INCOME STATEMENT
4

5. © Vlerick Business School
APPLE: PROFIT AND LOSS ACCOUNT (P&L)
5

6. © Vlerick Business School
DO YOU KNOW…
6

7. © Vlerick Business School
AN UNFORESEEN OUTCOME…
7

8. © Vlerick Business School
LIPITOR
 Peak sales
 Cumulative sales (1996-2012)
8

9. © Vlerick Business School
PFIZER: PROFIT AND LOSS ACCOUNT (P&L)
9

12. 12

13. 13

14. 14

15. 15

16. 16

17. 17

18. 18

19. © Vlerick Business School
GALAPAGOS
19

20. © Vlerick Business School
GALAPAGOS: P&L
20

21. © Vlerick Business School21

22. © Vlerick Business School
GALAPAGOS: ASSETS
22

23. © Vlerick Business School
GALAPAGOS: EQUITY AND LIABILITIES
23

24. © Vlerick Business School
GALAPAGOS: CASH FLOW STATEMENT
24

25. © Vlerick Business School
A LOT OF BIG PHARMA & SMALL BIOTECH
DEALS
 M&A, alliances, milestone payments, co-
development, licencsing out,…
 Clear complementarities
25